hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06289673, orgStudyIdInfo id: INITIALL, secondaryIdInfos id: NCI-2024-01659, type: REGISTRY, domain: NCI Clinical Trial Registration Program, briefTitle: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2034-05, completionDateStruct date: 2039-05, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: St. Jude Children's Research Hospital, class: OTHER, descriptionModule briefSummary: The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Leukemia (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment.Primary Objectives* To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies.* To develop a central database of genomic and clinical findings.Secondary Objectives* To assess event free and overall survival data of patients enrolled on this study., conditionsModule conditions: Acute Lymphoblastic Leukemia, conditions: Lymphoblastic Lymphoma, conditions: Mixed Phenotype Acute Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 850, type: ESTIMATED, armsInterventionsModule interventions name: Dexamethasone, interventions name: Vincristine, interventions name: Daunorubicin, interventions name: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), interventions name: Methotrexate, interventions name: Cytarabine, outcomesModule primaryOutcomes measure: Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy)., primaryOutcomes measure: Complete data within the INITIALL database, secondaryOutcomes measure: Event Free Survival (EFS), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: United States, Tennessee St. Jude Children's Research Hospital, city: Memphis, state: Tennessee, zip: 38105, country: United States, contacts name: Seth E. Karol, MD, role: CONTACT, phone: 866-278-5833, email: referralinfo@stjude.org, contacts name: Seth E. Karol, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.14953, lon: -90.04898, hasResults: False
protocolSection identificationModule nctId: NCT06289647, orgStudyIdInfo id: 19-28923B, secondaryIdInfos id: 5UG1EY030833, type: NIH, link: https://reporter.nih.gov/quickSearch/5UG1EY030833, briefTitle: Azithromycin Reduction to Reach Elimination of Trachoma B, acronym: ARRET, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2029-08-31, completionDateStruct date: 2029-08-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, collaborators name: Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, collaborators name: National Eye Institute (NEI), descriptionModule briefSummary: The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maniema, DRC. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution., conditionsModule conditions: Trachoma, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double (Investigator, Outcomes Assessor), whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100000, type: ESTIMATED, armsInterventionsModule interventions name: Azithromycin, outcomesModule primaryOutcomes measure: Ocular chlamydia measured in a population-based sample of 0-9 year-old children, secondaryOutcomes measure: Infectious load of chlamydia among 0-9-year-old children infected with ocular chlamydia, secondaryOutcomes measure: Conjunctival inflammation, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of California, San Francisco, city: Kindu, state: Maniema, country: Congo, The Democratic Republic of the, geoPoint lat: -2.94373, lon: 25.92237, hasResults: False
protocolSection identificationModule nctId: NCT06289621, orgStudyIdInfo id: 2024P000420, secondaryIdInfos id: K01TW012180, type: NIH, link: https://reporter.nih.gov/quickSearch/K01TW012180, briefTitle: Brief Transdiagnostic Treatment for Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) in South Africa, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-07-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: University of Stellenbosch, collaborators name: Fogarty International Center of the National Institute of Health, collaborators name: Harvard Medical School (HMS and HSDM), descriptionModule briefSummary: The purpose of this study is to examine the use of a brief transdiagnostic treatment for anxiety disorders and (post-traumatic stress disorder (PTSD) in South Africa. The intervention will be delivered by non-specialist providers (e.g., nurses) in primary care clinics. The brief intervention group will be compared to an enhanced standard care control group., conditionsModule conditions: Anxiety Disorders, conditions: Post-traumatic Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a Type 1 hybrid-effectiveness implementation trial. Study participants are randomized into the brief transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD) or an enhanced standard care control group., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: False Safety Behavioral Elimination Treatment (FSET), interventions name: Enhanced Standard Care, outcomesModule primaryOutcomes measure: Structured Clinical Interview for the DSM-5 (SCID-5), primaryOutcomes measure: Clinician-Administered PTSD Scale for the DSM-5 (CAPS), primaryOutcomes measure: Work Social Adjustment Scale (WSAS), primaryOutcomes measure: General Anxiety Disorder-7 (GAD-7), primaryOutcomes measure: Beck Anxiety Inventory (BAI), primaryOutcomes measure: Safety Aid Scale (SAS), secondaryOutcomes measure: Post-traumatic Disorder Checklist (PCL-5 PTSD Checklist (PCL-5), secondaryOutcomes measure: Patient Health Questionnaire - 9 (PHQ-9), secondaryOutcomes measure: Beck Depression Inventory (BDI), secondaryOutcomes measure: Anxiety Sensitivity Index -3, otherOutcomes measure: Life Events Checklist (LEC), otherOutcomes measure: Alcohol Use Disorders Identification Test (AUDIT), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06289608, orgStudyIdInfo id: ID_2024, briefTitle: Bruxism and Underlying Psichological Factors, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Salamanca, class: OTHER, descriptionModule briefSummary: The aim of this study was o determine the relationship between self-reported bruxism (SB) and some psychological factors (i.e: Anxiety State-Trait; Stress Reactivity Index, Beck Depression Inventory). A consecutive sample of 101 patients that reported at least 2 of the 6 items of Bruxism self-reported index, were explored clinically for quantifying the number and severity of worn teeth, and also the severe and location of the muscular pain according to an standardized inventory., conditionsModule conditions: Bruxism, conditions: Muscular Disorders, Atrophic, conditions: Temporomandibular Joint Disorders, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Depression Level, primaryOutcomes measure: Stress Level, primaryOutcomes measure: Anxiety, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinica Odontológica de la Universidad de Salamanca, status: RECRUITING, city: Salamanca, zip: 37007, country: Spain, contacts name: JAVIER MONTERO, DDS, role: CONTACT, phone: 619429971, email: javimont@usal.es, geoPoint lat: 40.96882, lon: -5.66388, hasResults: False
protocolSection identificationModule nctId: NCT06289595, orgStudyIdInfo id: Pro00134382, briefTitle: Impact of Photobiomodulation on Pain Associated With Orthodontic Treatment, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-03, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-02-20, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: PBM Healing International Limited, class: INDUSTRY, descriptionModule briefSummary: Orthodontic treatment can cause pain. Research studies have shown that light therapy can help reduce pain that is caused by orthodontic treatment. In this study, data was collected from the medical charts of patients who had orthodontic treatment and recorded their pain levels for 1 week at the beginning of orthodontic treatment while they used a light therapy device or did not use at device. This collected information was used to see if the light therapy device could lessen orthodontic pain., conditionsModule conditions: Orthodontic, conditions: Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: PBM Ortho device, outcomesModule primaryOutcomes measure: Level of Pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bio Dental Clinic Ashiya, city: Ashiya, country: Japan, geoPoint lat: 34.72807, lon: 135.30264, locations facility: Sawa Dental Clinic, city: Kasugai, country: Japan, geoPoint lat: 35.24762, lon: 136.97229, locations facility: Soejima Dental Clinic, city: Kitakyushu, country: Japan, geoPoint lat: 33.85181, lon: 130.85034, locations facility: Higashimachigran Dental Clinic, city: Kumamoto, country: Japan, geoPoint lat: 32.80589, lon: 130.69182, locations facility: Tsujimura Dental Clinic, city: Tanabe, country: Japan, geoPoint lat: 33.73333, lon: 135.36667, locations facility: IXI Family Dental Clinic, city: Tokyo, country: Japan, geoPoint lat: 35.6895, lon: 139.69171, locations facility: Miki Dental Clinic, city: Tokyo, country: Japan, geoPoint lat: 35.6895, lon: 139.69171, hasResults: False
protocolSection identificationModule nctId: NCT06289582, orgStudyIdInfo id: R24-004, briefTitle: Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-06, completionDateStruct date: 2027-06, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, collaborators name: Michael J. Fox Foundation for Parkinson's Research, descriptionModule briefSummary: The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval.Primary Objectives* To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.* To determine the longitudinal change in \[18F\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants.Secondary Objectives* To evaluate the correlation between baseline \[18F\]DPA-714 and PPMI clinical and biomarker outcomes.* To evaluate the correlation between the longitudinal change of \[18F\]DPA-714 and PPMI clinical and biomarker outcomes* To acquire safety data following injection of \[18F\]DPA-714, conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: [F-18]DPA714 administration IV, outcomesModule primaryOutcomes measure: Measure baseline and follow up regional brain TSPO levels using [18F]DPA-714-PET in prodromal PD., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UAB, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Evan Hudson, BS, role: CONTACT, phone: 205-934-6499, email: evanhudson@uabmc.edu, contacts name: Jonathan McConathy, MD,PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06289569, orgStudyIdInfo id: PRO00037243, briefTitle: Home Tele Rehabilitation Therapy for Vascular Dementia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2026-03-14, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: The Methodist Hospital Research Institute, class: OTHER, descriptionModule briefSummary: To determine whether the home telerehabilitation therapy is feasible and lessens caregiver burden in chronic stroke patients with and without vascular dementia (VaD), conditionsModule conditions: Dementia, Vascular, conditions: Stroke Sequelae, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Self-report measures will be not blinded, assessors will be blinded to treatment phase (SOC or telerehabilitation), enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Home telerehabilitation therapy, outcomesModule primaryOutcomes measure: Burden Scale for Family Caregivers, primaryOutcomes measure: Adverse events, secondaryOutcomes measure: Fugl-Meyer Upper extremity assessment, secondaryOutcomes measure: Wolf Motor Function Test (WMFT), otherOutcomes measure: Exercise log, otherOutcomes measure: Stroke Impact Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 110 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06289556, orgStudyIdInfo id: TEMP0001, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06289543, orgStudyIdInfo id: BVU-ESTELOGLU, briefTitle: Preoperative Oral Carbohydrate on Gastric Emptying, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Bezmialem Vakif University, class: OTHER, descriptionModule briefSummary: The current preoperative fasting guidelines recommend, applying preoperative carbohydrate solution 2 hours before the operation to minimize prolonged fasting time potential negative effects and improve patient comfort. Fasting after midnight before the operation day is a widespread practice. The major obstacle to preoperative carbohydrate solutions becoming prevalent and extremely long fasting time is the limited product; which is proven safe and efficient, and unavailable in several countries. In this study, our objective is to analyze the gastric volume, preoperative anxiety, stress response, postoperative insulin resistance, and postoperative nausea and vomiting by utilizing a low osmolality oral carbohydrate solution prepared with ginger and melissa., conditionsModule conditions: Vomit Aspiration, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Preoperative carbohydrate solution, outcomesModule primaryOutcomes measure: Gastric volume, secondaryOutcomes measure: preoperative anxiety, secondaryOutcomes measure: postoperative nausea and vomiting, secondaryOutcomes measure: thirst, hunger, fatigue, dry mouth, secondaryOutcomes measure: Postoperative Pain Score, secondaryOutcomes measure: postoperative insulin resistance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bezmialem University, status: RECRUITING, city: Istanbul, state: Fatih, country: Turkey, contacts name: Kazim Karaaslan, role: CONTACT, phone: +905055213865, email: kazimkaraslan@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-01-01, uploadDate: 2024-01-24T06:51, filename: Prot_SAP_000.pdf, size: 439034, hasResults: False
protocolSection identificationModule nctId: NCT06289530, orgStudyIdInfo id: 2023XAGG0070-1, briefTitle: Association Between Perioperative Blood and Interstitial Fluid Glucose Level and Clinically Relevant Postoperative Pancreatic Fistula in Different Pancreatic Surgeries, acronym: CR-POPF, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: This observational study was conducted in patients undergoing elective pancreaticoduodenectomy or distal pancreatectomy. It mainly answers the following two main questions:1. What are the risk factors for clinically relevant postoperative pancreatic fistula in different pancreatic surgeries?2. What is the correlation between perioperative blood and interstitial fluid glucose level and clinically relevant postoperative pancreatic fistula in different pancreatic surgeries？Participants were not required to perform additional research work other than the usual postoperative follow-up within 30 days after surgery. No control group was set in this study, and no additional clinical intervention was performed., conditionsModule conditions: Postoperative Pancreatic Fistula, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 600, type: ESTIMATED, outcomesModule primaryOutcomes measure: Clinically relevant postoperative pancreatic fistula, secondaryOutcomes measure: Bile leakage, secondaryOutcomes measure: Chyle leak, secondaryOutcomes measure: Postpancreatectomy hemorrhage, secondaryOutcomes measure: Abdominal infection, secondaryOutcomes measure: Delayed gastric emptying, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: LING LAN, MD, role: CONTACT, email: lanling_1988@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06289517, orgStudyIdInfo id: 68Ga-Her2-affibody, briefTitle: PET Imaging of 68Ga-Her2-affibody in Tumors With High Her2 Expression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Peking University First Hospital, class: OTHER, descriptionModule briefSummary: This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors., conditionsModule conditions: Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 68Ga-Her2-affibody, outcomesModule primaryOutcomes measure: The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer, secondaryOutcomes measure: The dosimetry of 68Ga-Her2-affibody, secondaryOutcomes measure: Quantitative evaluation of 68Ga-Her2-affibody, secondaryOutcomes measure: Correlation with pathological expression, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University First Hospital, city: Beijing, state: Beijing, zip: 100034, country: China, contacts name: Lei Yin, Dr., role: CONTACT, phone: +861083575252, email: jack-yin@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False